Our focus has been on a multi-party business process that tracks a list of reagents, solvents, and excipients in a GMP sequence from the starting materials to the drug product. The current process is inefficient, lacks transparency and is cost prohibitive, due to legacy license-based technologies. Therefore, we have been exploring Blockchain as a technology to help overcome these existing challenges.
We chose to work with the Linux Foundation to reinforce our commitment to open source, access their broad and influential ecosystem, as well leverage their expertise and experience.
Today, as a direct result of this work, we officially become a member of the Linux Foundation and the first pharmaceutical company to join the Hyperledger Project.
“Eli Lilly and Company is a global healthcare leader that discovers and develops medicines to help people live longer, healthier, more active lives,” said Mike Meadows, CTO, Eli Lilly & Company. “We believe healthcare is on the verge of a technology revolution. As a result, we are excited to join The Linux Foundation and Hyperledger, reinforcing our commitment to the open-source community and partnering on the potential for blockchain technologies within healthcare.”
Additional details regarding the membership can be found in the full Linux Foundation Press Release.
Due to the sensitivity of the use case, I am unable to share additional details at this time. However, we are keen to contribute to the open source community, therefore plan to share our technical experiences, feedback, and recommendations on Hyperledger over the coming months.